The abstract is read at the publisher; the summary is JClub's.
Eplontersen (45 mg every 4 weeks) did not reduce the 140-week risk of a composite of cardiovascular death and recurrent cardiovascular events in patients with ATTR-CM (rate ratio 0.89; P=0.28).
- Why it matters: ATTR-CM is progressive and life-threatening, and while eplontersen lowers hepatic TTR production, its clinical benefit in this cardiomyopathy population was uncertain.
- What they did: In a phase 3, international, double-blind trial, 1432 randomized patients received subcutaneous eplontersen or placebo plus standard treatment, with the primary endpoint tracked through week 140.
- The result: Primary events occurred in 210/715 (29.4%) with eplontersen versus 231/717 (32.2%) with placebo, and serious adverse events were similar (57.8% vs 59.4%), implying no clear reduction in risk.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.